Đang chuẩn bị liên kết để tải về tài liệu:
Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antibodies nivolumab and ipilimumab cannot penetrate and pass an intact blood brain barrier (BBB). | Intracranial antitumor responses of nivolumab and ipilimumab A pharmacodynamic and pharmacokinetic perspective a scoping systematic review